Value-Driven Specialty Pharmacies Highlight SPT Week in Review

Top five articles of the week from Specialty Pharmacy Times.

5. FDA Approves Expanded Use for Regorafinib to Treat Liver Cancer

Stivarga is the first FDA-approved treatment for hepatocellular carcinoma in almost a decade.https://www.specialtypharmacytimes.com/news/fda-approves-expanded-use-for-regorafinib-to-treat-liver-cancer

4. How Do Manufacturer Rebates Impact Drug Prices?

Study finds drug prices have been both increasing and decreasing for prescription drugs, independent of rebates.https://www.specialtypharmacytimes.com/news/how-do-manufacturer-rebates-impact-drug-prices3. Health Reform: How is Pharma Affected?

Various health reform approaches may affect each pharmaceutical manufacturer differently.https://www.specialtypharmacytimes.com/news/health-reform-how-is-pharma-affected

2. Expedited Specialty Drug Approvals From Multiple Points of View

While the job of the FDA is to protect the public from ineffective drugs, patients in need of life-saving treatments push for accelerated approval of specialty drugs.https://www.specialtypharmacytimes.com/news/expedited-specialty-drug-approvals-from-multiple-points-of-view

1. Specialty Pharmacies Must be Value-Driven, Patient-Centric to Remain Competitive

Pharmacists and pharmacies have become key players in improving patient outcomes.https://www.specialtypharmacytimes.com/news/specialty-pharmacies-must-be-value-driven-patient-centric-to-remain-competitive